Fc variants with altered binding to FcRn
The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
1. A polypeptide comprising an Fc variant of a human IgG Fc polypeptide, wherein said Fc variant comprises a serine at position 434, and wherein numbering is according to the EU index in Kabat et al.
2. A polypeptide comprising an Fc variant according to claim 1 , wherein said polypeptide is an antibody.
3. A polypeptide according to claim 2 , wherein said polypeptide comprising an Fc variant has specificity for a target molecule that is selected from the group consisting of a cytokine, a soluble protein factor, and a protein expressed on cancer cells.
4. An antibody according to claim 2 , wherein said antibody is selected from the group consisting of a chimeric antibody, a humanized antibody, or a human antibody.
5. A polypeptide comprising an Fc variant according to claim 1 , wherein said polypeptide is an Fc fusion.
6. A method of producing a polypeptide comprising an Fc variant according to claim 1 , said method comprising providing a cell comprising a nucleic acid encoding said polypeptide, wherein said cell is cultured under conditions suitable for expression of said polypeptide.
7. A method according to claim 6 , wherein said nucleic acid is contained in an expression vector.
8. A host cell comprising a nucleic acid encoding a polypeptide comprising an Fc variant according to claim 1 .
9. An expression vector, wherein said expression vector encodes a polypeptide comprising an Fc variant according to claim 1 .